Platelet Rich Fibrin Versus Platelet Rich Plasma for Microneedling Treatment of Facial Photoaging

ConditionPhotoaging
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorChang Gung Memorial Hospital

About this trial

The present study was conducted for analyzing the efficacy and safety of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in photoaging therapy.

Specific arms:

1. The investigators will compare the photoaging improvement of PRF and PRP treated face before and after treatment by two blinded investigators. 2. The investigators will evaluate the improvement of each parameter of photoaging by Visia system, dermoscope, and optical coherence tomography. 3. The investigators will evaluate the safety of the treatment of PRF and PRP.

Each case will receive 3 sessions of injection therapies with one month interval (T0, T1, and T2). Each case will receive PRP therapy on one side of the face and PRF on the other side of face. The investigators will determine the treatment method for both sides of each case randomly by coin flapping before the study. The investigators will evaluate each case before each session of therapy (T0, T1, T2) as well as 1 (T3) and 3 months (T4) after final session of treatment.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Men or female patients older than 20 years old with facial photoaging (Glogau Scale type II)

The photoaging severity of bilateral face is symmetric.

Disqualifiers

Patients with thrombocytopenia, coagulopathy, hematopoietic malignancy.

Patients with severe inflammation over treated area, malignancy, keloid, or poor wound healing history.

Patients had received laser, radiofrequency, ultherapy over treated area within 6 months.

Patients had received botulism or filler injection over treated area within 12 months.

Trial design

Design model

Parallel

Treatments tested in this trial

  • platelet-rich fibin

    Procedure/Surgery

    Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich fibin therapy on one side of the face. The other side of the face was treated with platelet-rich palsma.

  • platelet-rich palsma

    Procedure/Surgery

    Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich palsma therapy on one side of the face. The other side of the face was treated with platelet-rich fibin.

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: platelet-rich fibinExperimental treatment 1 intervention
Group B: platelet-rich palsmaActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Global Aesthetic Improvement Scale

We will compare the photoaging improvement of PRF and PRP treated face before treatment and 3 months after last treatment by two blinded investigators using Global Aesthetic Improvement Scale (GAIS). GAIS, which is a 5-point scale wherein 5 = very much improved, 4 = much improved, 3 = improved, 2 = no change, and 1= worse.

Time frame
3 months after the last session of treatment

Secondary outcomes

1

Fitzpatrick wrinkle scale

To assess the severity of wrinkles of photoaging areas (minimum: 1, mild; maximum: 9, severe)

Time frame
3 months after the last session of treatment
2

Wrinkle Severity Rating scale

To assess the severity of wrinkles of photoaging areas (minimum: 1, absent; maximum: 5, extreme)

Time frame
3 months after the last session of treatment

Other outcomes

1

The scores of rhytids in VISIA system

Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response. (minimum: 1, worse; maximum: 100, severe)

Time frame
3 months after the last session of treatment
2

The scores of Textures in VISIA system

Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response. (minimum: 1, worse; maximum: 100, severe)

Time frame
3 months after the last session of treatment
3

The scores of Pores size in VISIA system

Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response. (minimum: 1, worse; maximum: 100, severe)

Time frame
3 months after the last session of treatment
4

The scores of Brown spots in VISIA system

Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response. (minimum: 1, worse; maximum: 100, severe)

Time frame
3 months after the last session of treatment

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: